Literature DB >> 12652389

Treatment and prevention of postherpetic neuralgia.

Robert H Dworkin1, Kenneth E Schmader.   

Abstract

There have been 4 recent major advances in the treatment of postherpetic neuralgia (PHN) that are based on the results of randomized, controlled trials. These advances are the demonstrations that gabapentin, the lidocaine patch 5%, and opioid analgesics are efficacious in patients with PHN, and the report that nortriptyline and amitriptyline provide equivalent analgesic benefits for patients with PHN but that nortriptyline is better tolerated. The results of these clinical trials are briefly reviewed, and their implications for the treatment of patients with PHN are discussed. Despite these treatment advances, many patients remain refractory to current therapy, and the prevention of PHN has therefore become an important focus of current research. Research on administration of the varicella-zoster vaccine to prevent herpes zoster and on treatment of patients who have herpes zoster with combined antiviral and analgesic therapy to prevent PHN is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652389     DOI: 10.1086/368196

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

Review 1.  Treatment of herpes zoster and postherpetic neuralgia.

Authors:  Robert W Johnson; Robert H Dworkin
Journal:  BMJ       Date:  2003-04-05

Review 2.  [Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Authors:  Miriam Wittek; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Klin (Munich)       Date:  2010-05-26

3.  Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.

Authors:  Hung Fu Tseng; Bruno Lewin; Craig M Hales; Lina S Sy; Rafael Harpaz; Stephanie Bialek; Yi Luo; Steven J Jacobsen; Kavya Reddy; Po-Yin Huang; Jeff Zhang; Sean Anand; Erin Mary Bauer; Jennifer Chang; Sara Y Tartof
Journal:  J Infect Dis       Date:  2015-06-01       Impact factor: 5.226

4.  Response to Dr Clearkin.

Authors:  G Williams; J A Olson
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

5.  Comment on 'Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK'.

Authors:  L Clearkin
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

6.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

Review 7.  Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.

Authors:  Pamela S Davies; Bradley S Galer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Testing the sensitivities of noncognate inhibitors to varicella zoster virus thymidine kinase: implications for postherpetic neuralgia therapy with existing agents.

Authors:  Lianjuan Yang; Xiaohui Mo; Hong Yang; Hejun Dai; Fei Tan
Journal:  J Mol Model       Date:  2014-06-25       Impact factor: 1.810

Review 9.  Herpes zoster associated hospital admissions in Italy: review of the hospital discharge forms.

Authors:  Giovanni Gabutti; Carlotta Serenelli; Alessandra Cavallaro; Pietro Ragni
Journal:  Int J Environ Res Public Health       Date:  2009-09-02       Impact factor: 3.390

Review 10.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.